Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NALIRIFOX in Locally Advanced Pancreatic Cancer
NCT06467565Phase 2Recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Dec 2023
- Primary completion
- Dec 2024
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of nanoliposomal irinotecan in pancreatic ductal adenocarcinoma (PDAC), sponsored by Jiangsu Provincial People's Hospital. Started Dec 2023; status: recruiting.
02
Drugs
nanoliposomal irinotecan
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06467565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06467565.